Emerging Role of Tumor-Educated Platelets As a New Liquid Biopsy Tool for Colorectal Cancer Publisher Pubmed



Razzaghi H¹ ; Khabbazpour M² ; Heidary Z³ ; Heiat M⁴ ; Shirzad Moghaddam Z⁵ ; Khoncheh A⁴ ; Zakidizaji M² Show Affiliations
Source: Archives of Iranian Medicine Published:2023

Abstract

Colorectal cancer (CRC) is a major cause of cancer-associated death universally. Currently, the diagnosis, prognosis, and treatment monitoring of CRC mostly depends on endoscopy integrated with tissue biopsy. Recently, liquid biopsy has gained more and more attention in the area of molecular detection and monitoring of tumors due to ease of sampling, and its safe, non-invasive, and dynamic nature. Platelets, despite their role in hemostasis and thrombosis, are known to have an active, bifacial relationship with cancers. Platelets are the second most common type of cell in the blood and are one of the wealthy liquid biopsy biosources. These cells have the potential to absorb nucleic acids and proteins and modify their transcriptome with regard to external signals, which are termed tumor-educated platelets (TEPs). Liquid biopsies depend on TEPs’ biomarkers which can be used to screen and also detect cancer in terms of prognosis, personalized treatment, monitoring, and prediction of recurrence. The value of TEPs as an origin of tumor biomarkers is relatively new, but platelets are commonly isolated using formidable and rapid techniques in clinical practice. Numerous preclinical researches have emphasized the potential of platelets as a new liquid biopsy biosource for detecting several types of tumors. This review discusses the potential use of platelets as a liquid biopsy for CRC. Copyright 2023 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License.